Advertisement
Canada markets closed
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7263
    -0.0001 (-0.01%)
     
  • CRUDE OIL

    82.64
    -0.09 (-0.11%)
     
  • Bitcoin CAD

    87,451.75
    +2,698.43 (+3.18%)
     
  • CMC Crypto 200

    1,310.69
    +425.15 (+48.01%)
     
  • GOLD FUTURES

    2,394.90
    -3.10 (-0.13%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • NASDAQ futures

    17,531.75
    -15.50 (-0.09%)
     
  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • CAD/EUR

    0.6823
    +0.0021 (+0.31%)
     

Valeant Pharmaceuticals’ U.S. Diversified Top Products after 4Q17

Valeant Pharmaceuticals’ U.S. Diversified Top Products after 4Q17

In 4Q17, Valeant Pharmaceuticals International’s (VRX) Wellbutrin generated revenues of $67 million, a 10% growth on a quarter-over-quarter basis. In 4Q17, Wellbutrin’s YoY (year-over-year) growth was flat.